- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
Patent holdings for IPC class A61K 31/553
Total number of patents in this class: 2526
10-year publication summary
|
145
|
128
|
162
|
144
|
173
|
159
|
181
|
265
|
281
|
192
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Genentech, Inc. | 4113 |
92 |
| Gilead Sciences, Inc. | 2226 |
89 |
| Amgen Inc. | 4431 |
53 |
| AstraZeneca AB | 2820 |
42 |
| Rigel Pharmaceuticals, Inc. | 505 |
41 |
| F. Hoffmann-La Roche AG | 7816 |
37 |
| Merck Sharp & Dohme LLC | 3737 |
36 |
| Takeda Pharmaceutical Company Limited | 2713 |
34 |
| Boehringer Ingelheim International GmbH | 4487 |
33 |
| Bristol-myers Squibb Company | 4747 |
32 |
| Novartis AG | 10224 |
29 |
| Insmed Incorporated | 282 |
29 |
| Eli Lilly and Company | 4106 |
26 |
| VALO Health, Inc. | 193 |
22 |
| Janssen Pharmaceutica N.V. | 3160 |
21 |
| Glaxosmithkline Intellectual Property Development Limited | 779 |
21 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 715 |
21 |
| Daiichi Sankyo Company, Limited | 1890 |
20 |
| The Trustees of Columbia University in the City of New York | 3645 |
19 |
| Kumquat Biosciences Inc. | 84 |
19 |
| Other owners | 1810 |